Weight reduction and maintenance with IQP-PV-101: A 12-week randomized controlled study with a 24-week open label period

Weight Cycling and Mortality in a Large Prospective US Study

(2012) V. L. Stevens et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Anti-obesity drugs: past, present and future

(2012) R. J. Rodgers et al.   Disease Models & Mechanisms

A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): A review of clinical studies on weight loss and glycemic control

(2011) Marilyn L Barrett et al.   Nutrition Journal

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

(2010) Frank L Greenway et al.   LANCET

Possible anti-obesity therapeutics from nature – A review

(2010) Jong Won Yun   PHYTOCHEMISTRY

An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects

(2009) Charles S. Wilcox et al.   ADDICTIVE BEHAVIORS

Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates

(2009) Frank M. Sacks et al.   NEW ENGLAND JOURNAL OF MEDICINE

The psychiatric side-effects of rimonabant

(2009) Fabrício A. Moreira et al.   REVISTA BRASILEIRA DE PSIQUIATRIA

Obesity prevalence from a European perspective: a systematic review

(2008) Anne Berghöfer et al.   BMC PUBLIC HEALTH

The epidemiology of obesity: the size of the problem

(2008) W. P. T. James   JOURNAL OF INTERNAL MEDICINE

Management of Obesity in Adults: European Clinical Practice Guidelines

(2008) Constantine Tsigos et al.   Obesity Facts